IMVT vs. KRYS, IOVA, CRSP, SWTX, HALO, IMCR, IBRX, ACLX, UTZ, and TWST
Should you be buying Immunovant stock or one of its competitors? The main competitors of Immunovant include Krystal Biotech (KRYS), Iovance Biotherapeutics (IOVA), CRISPR Therapeutics (CRSP), SpringWorks Therapeutics (SWTX), Halozyme Therapeutics (HALO), Immunocore (IMCR), ImmunityBio (IBRX), Arcellx (ACLX), Utz Brands (UTZ), and Twist Bioscience (TWST).
Immunovant (NASDAQ:IMVT) and Krystal Biotech (NASDAQ:KRYS) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, community ranking, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.
47.1% of Immunovant shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 4.8% of Immunovant shares are owned by company insiders. Comparatively, 14.1% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Immunovant presently has a consensus price target of $48.00, suggesting a potential upside of 61.29%. Krystal Biotech has a consensus price target of $171.00, suggesting a potential upside of 8.45%. Given Immunovant's higher probable upside, analysts clearly believe Immunovant is more favorable than Krystal Biotech.
In the previous week, Krystal Biotech had 22 more articles in the media than Immunovant. MarketBeat recorded 28 mentions for Krystal Biotech and 6 mentions for Immunovant. Immunovant's average media sentiment score of 1.08 beat Krystal Biotech's score of 0.12 indicating that Immunovant is being referred to more favorably in the media.
Krystal Biotech received 169 more outperform votes than Immunovant when rated by MarketBeat users. However, 76.22% of users gave Immunovant an outperform vote while only 66.83% of users gave Krystal Biotech an outperform vote.
Immunovant has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500.
Krystal Biotech has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.
Krystal Biotech's return on equity of -13.31% beat Immunovant's return on equity.
Summary
Krystal Biotech beats Immunovant on 11 of the 15 factors compared between the two stocks.
Get Immunovant News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immunovant Competitors List
Related Companies and Tools
